EX-10.2
from 8-K
8 pages
Certain Portions of This Exhibit Have Been Redacted Because the Information Is Both (I) Not Material and (II) the Type That the Registrant Treats as Private or Confidential. Redacted Information Has Been Noted in This Document With a Placeholder Identified by the Mark “[*]”. Supplement to the Loan and Security Agreement Dated as of June 28, 2024 Among Cytosorbents Corporation (“Parent”) and Cytosorbents Medical Inc. (“Medical”; and Together With Parent, Jointly and Severally, Individually and Collectively, “Borrower”) Avenue Capital Management II, L.P., a Delaware Limited Partnership, as Administrative Agent and Collateral Agent (In Such Capacity “Agent”) and Avenue Venture Opportunities Fund, L.P. II, a Delaware Limited Partnership (“Avenue 2”), as a Lender and Avenue Venture Opportunities Fund, L.P., a Delaware Limited Partnership (“Avenue”), as a Lender
12/34/56
EX-10.1
from 8-K
31 pages
Certain Portions of This Exhibit Have Been Redacted Because the Information Is Both (I) Not Material and (II) the Type That the Registrant Treats as Private or Confidential. Redacted Information Has Been Noted in This Document With a Placeholder Identified by the Mark “[*]”. Loan and Security Agreement Dated as of June 28, 2024 Among Cytosorbents Corporation, a Delaware Corporation, (“Parent”) and Cytosorbents Medical Inc. a Delaware Corporation, (“Medical”; and Together With Parent, Jointly and Severally, Individually and Collectively, “Borrower”) and Avenue Capital Management II, L.P., a Delaware Limited Partnership (As Administrative Agent and Collateral Agent (In Such Capacity “Agent”) and Avenue Venture Opportunities Fund II, L.P., a Delaware Limited Partnership, (“Avenue 2“) as a Lender and Avenue Venture Opportunities Fund, L.P., a Delaware Limited Partnership (“Avenue“) as a Lender (In Such Capacity, With Avenue 2, a “Lender” and Collectively, the “Lenders”) Loan and Security Agreement
12/34/56